Bio-AMS enhances the activity of rifampicin and ethambutol in vitro

Slides:

Advertisements

Similar presentations

First-in-Human Testing of a Wirelessly Controlled Drug Delivery Microchip by Robert Farra, Norman F. Sheppard, Laura McCabe, Robert M. Neer, James M. Anderson,

Advertisements

Dose and range (mg/kg body weight)

Fig. 1 CSF1 is increased in blood of melanoma patients and correlates with disease progression. CSF1 is increased in blood of melanoma patients and correlates.

LTB4 production is elevated in preclinical and clinical lymphedema

Fig. 2. Effects of AZD4785 on proliferation and MAPK pathway signaling in KRAS mutant and wild-type cancer cells in vitro. Effects of AZD4785 on proliferation.

Fig. 5. S. hominis A9 isolated from normal human skin produces unique lantibiotics. S. hominis A9 isolated from normal human skin produces unique lantibiotics.

Differentiation of AZD4785 from MAPK pathway inhibitors in vitro

Fig. 6. dAST directly from clinical samples using dPCR and dLAMP for quantification. dAST directly from clinical samples using dPCR and dLAMP for quantification.

Fig. 3. Cytokines trigger proliferation and block differentiation of perivascular adipocytes. Cytokines trigger proliferation and block differentiation.

Fig. 5. Circulating PPi concentration does not correlate with severity of calcification phenotype in mice. Circulating PPi concentration does not correlate.

Fig. 3 Urinary LAM concentration predicted pulmonary TB and correlated to mycobacterial burden and weight loss. Urinary LAM concentration predicted pulmonary.

Fig. 3. Antimicrobial activity is detected in diverse strains of CoNS and not predictable at the species level. Antimicrobial activity is detected in diverse.

Fig. 2. dAST using dPCR is robust to the presence of high concentrations of commensal bacteria due to the specificity of NA amplification. dAST using dPCR.

Fig. 2. In vitro profiling of tEV markers on cell line–derived EVs.

Fig. 4. Biomechanical properties of treated tibiae.

JQ1 directly represses the promoter activities of BRCA1 and RAD51

Fig. 8. In vivo suppression of MM by CMLD

Fig. 6 Bimodal treatment results in reduced tinnitus loudness and reduced TFI scores in human patients. Bimodal treatment results in reduced tinnitus loudness.

PVSRIPO-mediated APC activation occurs in immunosuppressive conditions

Fig. 3. Serum HBsAg and liver HBV mRNA reduction in chimpanzees dosed with ARC-520. Serum HBsAg and liver HBV mRNA reduction in chimpanzees dosed with.

Fig. 6. Increased efficacy of immunotherapy in lymphangiogenic B16 melanomas depends on CCR7 signaling before therapy and local activation and expansion.

Fig. 8. mRIPO elicits neutrophil influx followed by DC and T cell infiltration into tumors. mRIPO elicits neutrophil influx followed by DC and T cell infiltration.

Fig. 2. GPC3 expression in normal and tumor tissues.

Fig. 5. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic mice. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic.

Increased ADMA in pregnancy is associated with SGA birth outcomes

Fig. 1. Working principle of the plasmon sensor chip (NPS) for tEVs.

Fig. 1 Chemical inactivation of BPL kills Mtb and prevents growth in mouse macrophages. Chemical inactivation of BPL kills Mtb and prevents growth in mouse.

Fig. 4 CXCL4 potentiates TLR8-mediated activation of SSc pDCs.

Fig. 5. Stimulation of EPO expression and secretion under hypoxic culture conditions. Stimulation of EPO expression and secretion under hypoxic culture.

Fig. 5. Toxin production and release in vitro.

Fig. 7 Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors. Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors.

Fig. 5. In vivo characterization of adipogenesis by CT.

Fig. 6. A circadian rhythm in keratinocyte wound healing and a diurnal variation in human burn healing outcome. A circadian rhythm in keratinocyte wound.

Fig. 4. MATE1 transcription in RCC.

Fig. 6. Safety assessment in cynomolgus monkey.

Fig. 6 ROC curves of mCCNA1 and mVIM assayed on esophageal balloon samplings of the distal esophagus. ROC curves of mCCNA1 and mVIM assayed on esophageal.

Fig. 4 Nanocages captured multiple TB-related analytes.

Fig. 4. BET inhibition sensitizes HR-proficient tumors to PARPi treatment in vivo. BET inhibition sensitizes HR-proficient tumors to PARPi treatment in.

Fig. 4. Actin polymerization rhythms are required for circadian regulation of adhesion and wound-healing efficacy by fibroblasts. Actin polymerization.

Fig. 1. Experimental workflow of the dAST method and computationally estimated operational space. Experimental workflow of the dAST method and computationally.

Fig. 2. Circulating VEGF in GCA patients up-regulates microvascular endothelial Jagged1. Circulating VEGF in GCA patients up-regulates microvascular endothelial.

Persistence of CAR4 cells is reduced after sustained TCR engagement

Fig. 7 BRD0705 impairs colony formation in AML cell lines and patient cells and shows in vivo efficacy in multiple AML mouse models. BRD0705 impairs colony.

Fig. 7 Human study design for device testing.

Antiproliferative effects of JQ-EZ-05 on VHL−/− ccRCC are on-target

Fig. 3. Recovery of AVP-deficient rats from anemia induced by sublethal irradiation. Recovery of AVP-deficient rats from anemia induced by sublethal irradiation.

Fig. 2. Pathways differentially regulated in patients with early Lyme disease and STARI. Pathways differentially regulated in patients with early Lyme.

Workflow of a sample-to-answer AST performed in less than 30 min

Fig. 1. Drug combination screen identifies BETi as acting synergistically with PARPi. Drug combination screen identifies BETi as acting synergistically.

Fig. 1. Map showing the study catchment area in the East of England.

Fig. 3. β-AR signaling induces IL-6 in NSCLC cells via activation of PKC and CREB. β-AR signaling induces IL-6 in NSCLC cells via activation of PKC and.

Fig. 5 CXCL4 potentiates TLR9-mediated activation but has minimal effect on TLR7-mediated activation of pDCs purified from SSc or HDs. CXCL4 potentiates.

Fig. 7 DMN-Tre labeling of Mycobacterium tuberculosis is inhibited by tuberculosis drug cocktail, unlike auramine staining. DMN-Tre labeling of Mycobacterium.

Fig. 2 Analysis of CLL lymph nodes.

Fig. 2. IL-2/rapamycin–expanded T cells express homing receptors to traffic to lymphoma sites and are resistant to SN-38 toxicity. IL-2/rapamycin–expanded.

Fig. 4. The effect of single-dose rozanolixizumab on the concentration of IgG subtypes in healthy subjects. The effect of single-dose rozanolixizumab on.

Fig. 6. Analysis of SHIV-325c V1V2 envelope sequences in breakthrough infections. Analysis of SHIV-325c V1V2 envelope sequences in breakthrough infections.

Fig. 1 Antibiotic-induced metabolome responses in M. smegmatis.

Bexarotene is neuroprotective in mouse and human HD neurons in vitro

Decreased weight and adiposity is transmissible via the gut microbiota

Fig. 5 BRD0705 induces differentiation in AML cell lines and primary patient samples through GSK3α-selective inhibition. BRD0705 induces differentiation.

Fig. 5 Early and modest immune response at day 3 after exposure in Delayed animals. Early and modest immune response at day 3 after exposure in Delayed.

Fig. 4. Clearance of 12-mer-1 from a nonhuman primate model.

Fig. 2. BET inhibition enhances PARPi-induced DNA damage.

Fig. 8. Zbtb7a deficiency impairs antigen presentation by AMs.

Fig. 4. Induced Zbtb7a in lungs is localized to AMs.

Fig. 2 AcPGP induces IL-8 and G-CSF release from human bronchial epithelial cells. AcPGP induces IL-8 and G-CSF release from human bronchial epithelial.

Fig. 2 Fabrication and in vitro release of TB antibiotics from individual drug pills. Fabrication and in vitro release of TB antibiotics from individual.

Fig. 1. Antituberculosis drug resistance rate (%) and pattern in sanatoria of North Korea: (A) patients (n = 489) in all sanatoria analyzed in this study,

Bio-AMS enhances the activity of rifampicin and ethambutol in vitro

Presentation transcript:

Fig. 5 Bio-AMS enhances the activity of rifampicin and ethambutol in vitro. Bio-AMS enhances the activity of rifampicin and ethambutol in vitro. (A to E) Impact of Bio-AMS on the activities of the TB drugs rifampicin (A and D), ethambutol (B and E), and isoniazid (C). The Mtb H37Rv strain was grown in standard liquid culture with Bio-AMS (1 μM in DMSO) or DMSO alone for 3 days, after which the bacteria were exposed to the other anti-TB drugs. Data are representative of two independent experiments with three samples per time point. Data are means ± SEM. Divya Tiwari et al., Sci Transl Med 2018;10:eaal1803 Published by AAAS